These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34368002)

  • 1. Neoadjuvant Immunotherapy of Oral Squamous Cell Carcinoma: Case Report and Assessment of Histological Response.
    Olmos M; Glajzer J; Büntemeyer TO; Frohwitter G; Ries J; Eckstein M; Hecht M; Lutz R; Kesting MR; Weber M
    Front Oncol; 2021; 11():720951. PubMed ID: 34368002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case report: Patient specific combination of surgery and immunotherapy in advanced squamous cell carcinoma of the head and neck - a case series and review of literature.
    Olmos M; Lutz R; Büntemeyer TO; Glajzer J; Nobis CP; Ries J; Möst T; Eckstein M; Hecht M; Gostian AO; Erdmann M; Foerster Y; Kesting M; Weber M
    Front Immunol; 2022; 13():970823. PubMed ID: 36389668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
    Poulose JV; Kainickal CT
    World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Response to Neoadjuvant Immunotherapy Combined with Targeted Therapy and Chemotherapy in Oral Squamous Cell Carcinoma: Experience in Three Patients.
    Tian Y; Zhang L; Jin N; Wan Z; Zhang H; Zhang H; Zhang L
    Onco Targets Ther; 2022; 15():353-359. PubMed ID: 35422629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations among pretreatment tumor necrosis and the expression of HIF-1α and PD-L1 in advanced oral squamous cell carcinoma and the prognostic impact thereof.
    Chen TC; Wu CT; Wang CP; Hsu WL; Yang TL; Lou PJ; Ko JY; Chang YL
    Oral Oncol; 2015 Nov; 51(11):1004-1010. PubMed ID: 26365985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant immunotherapy in resectable head and neck cancer: oral cavity carcinoma as a potential research model.
    Gutiérrez Calderón V; Cantero González A; Gálvez Carvajal L; Aguilar Lizarralde Y; Rueda Domínguez A
    Ther Adv Med Oncol; 2021; 13():1758835920984061. PubMed ID: 33747147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current studies of immunotherapy in head and neck cancer.
    Dogan V; Rieckmann T; Münscher A; Busch CJ
    Clin Otolaryngol; 2018 Feb; 43(1):13-21. PubMed ID: 28464441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy in head and neck cancer: aiming at EXTREME precision.
    Szturz P; Vermorken JB
    BMC Med; 2017 Jun; 15(1):110. PubMed ID: 28571578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The neoadjuvant paradigm reinvigorated: a review of pre-surgical immunotherapy in HNSCC.
    Stafford M; Kaczmar J
    Cancers Head Neck; 2020; 5():4. PubMed ID: 32195008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Neoadjuvant Pembrolizumab for Oral Cavity Squamous Cell Carcinoma With Adverse Events After Surgery in Treatment-Naive Patients.
    Tang AL; O'Neil T; McDermott S; Tripathi S; Tikhtman R; Mark JR; Patil Y; Tabangin M; Altaye M; Wise-Draper TM; Zender CA
    JAMA Otolaryngol Head Neck Surg; 2022 Oct; 148(10):935-939. PubMed ID: 36006622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Microenvironment in Oral Cancer Following Neoadjuvant Pembrolizumab: Preliminary Analysis of the Histopathologic Findings.
    Dobriyan A; Gluck I; Alon E; Barshack I; Yahalom R; Vered M
    Front Oral Health; 2021; 2():653104. PubMed ID: 35048002
    [No Abstract]   [Full Text] [Related]  

  • 13. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer.
    Lim SH; Hong M; Ahn S; Choi YL; Kim KM; Oh D; Ahn YC; Jung SH; Ahn MJ; Park K; Zo JI; Shim YM; Sun JM
    Eur J Cancer; 2016 Jan; 52():1-9. PubMed ID: 26623522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial.
    Eichhorn F; Klotz LV; Bischoff H; Thomas M; Lasitschka F; Winter H; Hoffmann H; Eichhorn ME
    BMC Cancer; 2019 May; 19(1):413. PubMed ID: 31046714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
    Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
    Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
    Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!
    Maio M; Blank C; Necchi A; Di Giacomo AM; Ibrahim R; Lahn M; Fox BA; Bell RB; Tortora G; Eggermont AMM
    Eur J Cancer; 2021 Jul; 152():155-164. PubMed ID: 34107449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage Treatment Using Anti-PD-1/CTLA-4 Immunotherapy After Failure of Neoadjuvant Chemotherapy in Microsatellite Instable Gastroesophageal Carcinoma.
    Klein O; Brown WA; Saxon S; Haydon A
    Oncologist; 2021 Jun; 26(6):461-464. PubMed ID: 33856094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment.
    Hirai M; Kitahara H; Kobayashi Y; Kato K; Bou-Gharios G; Nakamura H; Kawashiri S
    Int J Oncol; 2017 Jan; 50(1):41-48. PubMed ID: 27922697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case report: reinitiating pembrolizumab treatment after small bowel perforation.
    Beck TN; Kudinov AE; Dulaimi E; Boumber Y
    BMC Cancer; 2019 Apr; 19(1):379. PubMed ID: 31018834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.